FOLH1 and prostate carcinoma: 18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid), a prostate-specific membrane antigen–targeting radiotracer, has shown promise as a prostate cancer imaging radiotracer.